Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) last traded at ₹241, a market capitalisation of ₹1,592 crore, on a P/E of 33.9. Over the past 52 weeks the stock has ranged between ₹155 and ₹265. Jagsonpal Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹82 crore and net profit of ₹13 crore. Jagsonpal Pharmaceuticals Ltd’s annual general meeting is scheduled for 18 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Jagsonpal Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Jagsonpal Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹82 cr, up 7.9% from ₹76 cr a year earlier. Net profit was ₹13 cr, up 18.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 75 | 74 | 59 | 76 | 74 | 73 | 64 | 82 |
| Expenses | 58 | 58 | 50 | 61 | 58 | 57 | 53 | 65 |
| Operating profit | 16 | 16 | 9 | 14 | 16 | 16 | 11 | 17 |
| OPM % | 22% | 21% | 15% | 19% | 22% | 22% | 17% | 21% |
| Other income | 2 | 26 | 3 | 3 | 3 | 1 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 15 | 39 | 9 | 14 | 17 | 15 | 12 | 18 |
| Tax % | 25% | 17% | 24% | 25% | 25% | 25% | 25% | 25% |
| Net profit | 11 | 32 | 7 | 11 | 13 | 11 | 9 | 13 |
| EPS (₹) | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 | 1.31 | 2.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Jagsonpal Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 188 | 218 | 237 | 209 | 269 | 287 | 294 |
| Operating profit | 19 | 26 | 34 | 23 | 51 | 58 | 61 |
| OPM % | 10% | 12% | 14% | 11% | 19% | 20% | 21% |
| Net profit | 17 | 19 | 27 | 22 | 55 | 43 | 45 |
| EPS (₹) | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 6.43 | 6.84 |
TTM is the trailing twelve months to the most recent quarter.
Jagsonpal Pharmaceuticals Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- 4%
- 10 Years
- 30%
- 5 Years
- 21%
- 3 Years
- 16%
- TTM
- 10%
- 10 Years
- 33%
- 5 Years
- 32%
- 3 Years
- 12%
- 1 Year
- 3%
- 10 Years
- 12%
- 5 Years
- 17%
- 3 Years
- 17%
- Last Year
- 17%
Jagsonpal Pharmaceuticals Ltd shareholding pattern
Promoters held 69.06% at Jun 2026, up from 67.65% at Jun 2025. FIIs 2.30% and DIIs 0.62%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 67.98% | 67.82% | 67.77% | 67.65% | 67.54% | 67.39% | 67.89% | 69.06% |
| FIIs | 2.30% | 2.10% | 2.10% | 2.17% | 2.12% | 2.12% | 2.44% | 2.30% |
| DIIs | 0.11% | 0.00% | 0.00% | 0.05% | 0.08% | 0.15% | 0.22% | 0.62% |
| Public | 29.63% | 30.10% | 30.11% | 30.12% | 30.25% | 30.34% | 29.44% | 28.04% |
| No. of shareholders | 15,633 | 18,471 | 21,085 | 22,899 | 24,653 | 24,895 | 26,264 | 24,181 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Jagsonpal Pharmaceuticals Ltd’s AGM?
Jagsonpal Pharmaceuticals Ltd’s annual general meeting is scheduled for 18 Sept 2026.
- AGM47th Annual General Meeting and final dividend approval
See the full results calendar for every Indian company reporting in the next 30 days.
Jagsonpal Pharmaceuticals Ltd corporate filings
- Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022Company Updatelow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals Limited has announced the allotment of 27,950 equity shares to…
Read the full analysis - Newspaper Advertisement- 47th Annual General Meeting of the Company to be held on September 18, 2026Company Updatelow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals has issued a newspaper advertisement confirming that its 47th…
Read the full analysis - Earning Call Transcript for meeting held on July 30, 2026Company Updatehigh impact
Cruxal's analysis: Jagsonpal Pharmaceuticals Limited delivered a robust Q1 FY27, with revenue from…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Jagsonpal Pharmaceuticals Ltd
Cruxal reads every Jagsonpal Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.